Dynavax Technologies Corporation (NASDAQ: DVAX) And Clover Biopharmaceuticals Announces Results For Their COVID-19 Vaccine

Dynavax Technologies Corporation (NASDAQ: DVAX)  has announced that Clover Biopharmaceuticals has released promising data for its protein-based COVID-19 vaccine SCB-2019 adjuvanted with CpG 1018 adjuvant. 

SPECTRA Study enrolled 30,000 subjects

The findings show that the SPECTRA, pivotal phase 2/3 clinical study, which enrolled more than 30,000 subjects, attained both primary and secondary endpoints.  Notably, vaccine efficacy was successfully shown in conditions where 100% of the SARs-Cov-2 varieties witnessed in the efficacy analysis were COVID-19. 

SCB-2019 was found to be 100% effective against severe COVID-19 and admissions and 84 % effective against moderate-to-severe COVID-19 resulting from any SARS-CoV-2 strain. Also, SCB-2019 showed an overall efficacy of 79% against COVID-19 severity due to the dominant Delta variant. Efficacy against the Gamma variant was 92%, and 59% against the Mu variant. It is vital to note that the Delta, Gamma, and Mu strains accounted for 73% of all strains found in the study. Overall efficacy against COVID-19 of any severity caused by any strain in the research was 67%, achieving the trial’s primary goal. Clover’s protein-based vaccine is among the first to show considerable efficacy against the Delta variant in a randomized, double-blind study.

Clover vaccine showed good tolerability 

Dynavax CEO Ryan Spencer said, “We are very pleased with the reported efficacy results demonstrated in the SPECTRA trial, especially considering that all cases were from variants. In addition to the positive efficacy results, the remarkable tolerability profile of the Clover vaccine adjuvanted with CpG 1018 could be a useful tool in overcoming vaccine hesitancy for more reactogenic platforms and for booster doses in the future. We believe these trial results demonstrate the value of our CpG 1018 adjuvant as part of the response to this pandemic and as a platform for the development of new and improved vaccines. We look forward to continuing to support Clover and the development of their COVID-19 vaccine, making it available to those in need around the world.”